Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

i3 Health

Optimizing Treatment Experiences in Castration-Resistant Prostate Cancer

Access Activity

Overview / Abstract:

STATEMENT OF NEED

Prostate cancer is the most common tumor type in men in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease process with a dearth of effective treatment options. Metastatic CRPC is the primary cause of prostate-related mortality, accounting for an estimated 29,430 deaths annually. Median overall survival remains less than 2 years.

TARGET AUDIENCE

Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with CRPC.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1.Summarize findings from recent clinical studies on novel combination and sequential treatment strategies for nonmetastatic and metastatic CRPC
2. Distinguish the safety and efficacy profiles of novel therapies for nonmetastatic and metastatic CRPC
3. Apply strategies to promote adherence to CRPC therapy and manage treatment-related adverse events

Expiration

Apr 30, 2020

Discipline(s)

Nurse Practitioner , Nursing CNE

Format

Online, Webinar / Webcast / Video

Credits / Hours

1.2

Accreditation

ANCC

Presenters / Authors / Faculty

Kathleen D. Burns, MSN, ANP, OCN® (Chairperson)
Nurse Practitioner, Division of Genitourinary Medical Oncology
City of Hope

Brenda Martone, MSN, ANP-BC, AOCNP
Nurse Practitioner
Northwestern Medicine

Sponsors / Supporters / Grant Providers

This activity is supported by independent educational grants from Bayer Healthcare Pharmaceuticals, Inc. and Sanofi/Genzyme.

Keywords / Search Terms

i3 Health i3 Health, prostate cancer, castration-resistant prostate cancer, CRPC, online CE, free CE, Free CE CME, free CEUs Free CE CME

Access Activity

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.